



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

BRD7-IN-2

Cat. No.:	HY-149420		
Molecular Formula:	C ₁₈ H ₁₈ N ₂ O ₃		
Molecular Weight:	310.35		
Target:	Epigenetic Reader Domain		
Pathway:	Epigenetics		
Storage:	Powder	-20°C	3 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 10 mg/mL (32.22 mM; Need ultrasonic)						
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg	
				1 mM	3.2222 mL	16.1108 mL	32.2217 mL
				5 mM	0.6444 mL	3.2222 mL	6.4443 mL
				10 mM	0.3222 mL	1.6111 mL	3.2222 mL
Please refer to the solubility information to select the appropriate solvent.							
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 1 mg/mL (3.22 mM); Clear solution						

BIOLOGICAL ACTIVITY

Description	BRD7-IN-2 (compound 2-77) is a potent inhibitor of bromodomain-containing protein 7 (BRD7), targeting to prostate cancer cells. BRD7-IN-2 is selective for BRD7 rather than BRD9, with IC ₅₀ s of 5.4 μM, and >300 μM, respectively.
IC ₅₀ & Target	IC ₅₀ : 5.4 μM (BRD7); Ki: 1.3 μM (BRD7)
In Vitro	BRD7-IN-2 (compound 2-77) inhibits BRD7 and BRD9 in HEK293T cells, with IC ₅₀ s of 1.1 μM and 3.2 μM, respectively ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Ordóñez-Rubiano SC, Maschinot CA, Wang S, Sood S, Baracaldo-Lancheros LF, Strohmier BP, McQuade AJ, Smith BC, Dykhuizen EC. Rational Design and Development of Selective BRD7 Bromodomain Inhibitors and Their Activity in Prostate Cancer. J Med Chem. 2023 Aug 24;66(16):11250-11270.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA